clinical trial · NCT06783114
A Clinical Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in Adults
Chongqing Claruvis Pharmaceutical Co., Ltd.·phase3·recruiting·n = 254
Upper Limb SpasticityRecombinant Botulinum Toxin Type A for injection (YY001)BOTOX®Placebo
brief summary
This is a randomized, double-blind, multi-center phase II/III study to evaluate the efficacy and safety of Recombinant Botulinum Toxin Type A (YY001) for injection in the treatment of upper limb spasticity in adults
started
Sep 14, 2024
primary completion
Sep 30, 2026
completion
Sep 30, 2026
last updated
Jan 22, 2026
official title
A Clinical Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in Adults (REHAB-1)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol